Article
Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Oncotarget - 26 Apr 2016
Lim Sun Min, Kim Eun Young, Kim Hye Ryun, Ali Siraj M, Greenbowe Joel R, Shim Hyo Sup, Chang Hyun, Lim Seungtaek, Paik Soonmyung, Cho Byoung Chul
Abstract excerpt
BACKGROUND: Identification of clinically relevant oncogenic drivers in advanced cancer is critical in selecting appropriate targeted therapy. Using next-generation sequencing (NGS)-based clinical cancer gene assay, we performed comprehensive genomic profiling (CGP) of advanced cases of lung adenocarcinoma. METHODS: Formalin-fixed paraffin-embedded tumors from 51 lung adenocarcinoma patients whose tumors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
